EVEric Venner

Eric Venner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Venner has a total of 788 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An oxidative mutational signature in normal tissues of a monoallelic MUTYH carrier

    by Christopher M Grochowski, Yang Zhang, Eric Venner, Marie-Claude Gingras, Sravya Bhamidipati, Ziad Khan, Jesse Farek, Luis F. Paulin, Yilei Fu, Chenghang Zong, et al.

    Biallelic loss of MUTYH causes MUTYH -associated polyposis (OMIM: 608456), characterized by the oxidative base-excision-repair mutational signature SBS18, but whether the roughly 1 in 100 individuals who carry a single pathogenic MUTYH allele acquire a mutational phenotype in normal tissue is unknown. Analysis of multi-tissue sequencing of 25 donors from the Somatic Mosaicism across Human Tissues (SMaHT) Network identified three heterozygous carriers of MUTYH p.Gly396Asp. One carrier showed SBS18 across multiple normal tissues, ranking first of 25 donors with three independent methods and remaining significant after adjustment for tissue, without a somatic, epigenetic or transcriptional second hit at the MUTYH locus. A single hypomorphic MUTYH allele can therefore leave a measurable oxidative mutational mark in healthy tissues, supporting tissue-level mutational readouts as an approach to cancer risk stratification within this common carrier state.

  • Frequency of pharmacogenomic variation and medication exposures among participants in the All of Us Research Program

    by Andrew Haddad, Aparna Radhakrishnan, Sean McGee, Joshua D. Smith, Jason H. Karnes, Eric Venner, Marsha M. Wheeler, Karynne Patterson, Kimberly Walker, Divya Kalra, et al.

    Pharmacogenomics promises improved outcomes through individualized prescribing. However, the lack of diversity in pharmacogenomics studies impedes clinical translation and the application of precision medicine across populations. We evaluated the frequencies of variants in 16 pharmacogenes ( ABCG2 , CACNA1S , CYP2D6 , CYP2C Cluster , CYP2C19 , CYP2C9 , CYP3A5 , CYP4F2 , DPYD , G6PD , NUDT15 , RYR1 , SLCO1B1 , TPMT , UGT1A1 , and VKORC1 ) and predicted phenotypes and medication exposures using whole-genome sequencing and electronic health record data from nearly 100,000 All of Us Research Program participants. We report that 100% of participants carried at least one pharmacogenomic variant and nearly all (99.5%) had a predicted phenotype with prescribing recommendations. Clinical impact was high with 24.4% of participants having both an actionable phenotype for these pharmacogenes and a prior exposure to an impacted medication with pharmacogenomic prescribing guidance. Importantly, we report thousands of previously unrecognized pharmacogene variants and hundreds of alleles and predicted phenotypes that deviate from known frequencies across populations or were previously unreported, especially in the Americas and African ancestry groups.


  • Open Access

    Genetic and Epigenetic Landscape of Self-Identified Hispanics/Latino in All Of Us

    by Adam C. English, Yilei Fu, Luis F. Paulin, Michal B. Izydorczyk, Sairam Behera, Qiuhui Li, Xinchang Zheng, Yiming Zhu, Justin Paschall, Grace E. Tietz, et al.

    Human genetic studies still underrepresent many populations, limiting discovery and interpretation of medically relevant variation. Extensive admixture in self-identified Hispanic/Latino populations increases the need for representative reference data and ancestry-aware interpretation of medically relevant variation. We used long-read sequencing to analyze genetic variation, ancestry, and DNA methylation in 1,490 self-identified Hispanic/Latino participants from the All of Us Research Program. We identified 10 million novel variants and more than 100 candidate phenotype associations, with fine-mapping prioritizing structural variants over nearby single-nucleotide variants in more than half. We linked 3,329 tandem repeats to DNA methylation, resolved widespread allele-specific methylation, and identified ancestry-linked regulation across paralogous genes. These results reveal previously inaccessible genetic and regulatory variation and show the value of long-read sequencing for diverse populations.

  • Open Access

    Integrated Clinical-Genomic Reanalysis Identifies Diagnostic Gaps and Candidate Genes in a Pediatric Rare Disease Cohort

    by Hyunjung Gu, Aniko Sabo, Sharayu V. Jangam, Hirokazu Hashimoto, Christina Y. Miyake, Bo Yuan, Charul Gijavanekar, Eric Venner, Viktoriya Korchina, Sarah H. Elsea, et al.

    Purpose: Children with suspected rare genetic disorders often remain undiagnosed after exome, gene panel, or chromosomal microarray testing. We sought to define recurrent missed-diagnosis mechanisms and evaluate an integrated clinical-genomic reanalysis framework. Methods: We studied 75 participants with rare or striking pediatric-onset phenotypes who remained undiagnosed after prior genetic testing. Trio genome sequencing evaluated SNVs, indels and copy-number variants. RNA sequencing was performed in 63 participants to assess aberrant expression and splicing, with targeted follow-up assays used selectively for prioritized variants. Clinician-genome scientist review integrated longitudinal phenotyping, physician input, and inheritance. Unresolved cases underwent research-level candidate prioritization. Results: Clinically reportable findings were returned in 9, including two with multilocus findings: 5 explained the primary phenotype and 4, while not fully explanatory, were clinically relevant and informing surveillance, management, or family follow-up. Previously missed findings reflected technical limitations, including deep intronic splice-altering variants supported by transcriptome analysis and a genomic deletion, and interpretive limitations related to incomplete phenotype integration or narrowly scoped prior testing. Research-level analysis prioritized six candidate genes, including biallelic ACHE variants with reduced enzymatic activity. Conclusion: Integrated clinical-genomic reanalysis framework identified diagnostic gaps, recovered care-informing findings, and prioritized candidate genes for rare disease discovery.

  • Open Access

    Performance Characteristics of Reasoning Large Language Models for Evidence Extraction from Clinical Genomics Literature

    by Mullai Murugan, Bo Yuan, Joshi Stephen, Charul Gijavanekar, Shengfeng Xu, Senkottuvelan Kadirvel, E. Andres Rivera-Munoz, Vitor Manita, Francisco Delca, Richard A. Gibba, et al.

    BACKGROUND: Genetic variant curation, an important step in the implementation of Genomic Medicine, requires literature-guided comparison of variant prevalence in affected individuals versus healthy controls. This evidence is categorized as the PS4 evidence code by the AMP/ACMG variant interpretation guidelines and its manual extraction is a major bottleneck in clinical variant curation. This study aimed to evaluate whether reasoning-capable large language models (LLMs) can support guideline-constrained PS4 evidence extraction from literature. METHODS: We benchmarked five LLMs for publication-level variant detection and PS4-eligible proband counting under ACMG/AMP and ClinGen Variant Curation Expert Panel (VCEP) guidance using an expert-curated truth-set. We assembled an expert-curated truth-set of 281 publication-variant pairs from 275 peer-reviewed publications (58 genes and 128 variants). Five LLMs spanning frontier-scale, reasoning-optimized, and efficiency-oriented classes (Gemini 2.5 Pro, GPT-5, o3, o4-mini, and Claude Sonnet 4) were evaluated against this truth-set using identical inputs, a unified prompt template, and a schema-constrained JSON output format on two tasks: (1) determining whether a prespecified variant was correctly identified and (2) counting independent PS4-eligible probands under applicable guidance. Primary outcomes were Task 1 accuracy and Task 2 exact-count concordance (model PS4 count equals truth-set count). We also assessed prompt sensitivity, error modes, and output variability across models. RESULTS: Models were able to detect the presence of a variant in a publication with high accuracy (93.6-97.9%). For PS4 case counting, exact-count concordance was highest for Gemini 2.5 Pro (91.1%) and GPT-5 (90.0%), followed by o3 (86.5%), o4-mini (79.4%), and Claude Sonnet 4 (73.0%). Most counting errors resulted from an inability of a model to correctly apply guidelines, including evaluating phenotype and family structure. Prompt refinements improved concordance for most models but reduced performance for Claude Sonnet 4, indicating model specific prompting may be warranted. CONCLUSIONS: Reasoning-capable LLMs can support automation of guideline-based PS4 evidence extraction, achieving high concordance with expert curation, but performance is model- and prompt-dependent and failures concentrate in applying guidelines. Our findings support a hybrid workflow for clinical use in which LLM outputs accelerate evidence extraction with expert escalation.

  • Open Access

    Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson’s disease

    by Ruth B. De-Paula, Jonggeol Kim, Herve Rhinn, Hiba Saade, Fatima Chavez, Téah Segura, Maria Valeria Lozano, Michelle Etoundi, Karla Silos, Viktoriya Korchina, et al.

    Risk variants in multiple genes, including GBA1 , strongly implicate lipid metabolism in Parkinson’s disease (PD) onset and progression. We show that common PD risk variants at the serine palmitoyltransferase small subunit B ( SPTSSB ) locus, a key regulator of de novo sphingolipid biosynthesis, are associated with increased SPTSSB brain expression and elevated plasma ceramides. Additional analyses strongly support our hypothesis that a common SPTSSB causal variant is responsible for PD risk as well as the expression and metabolic quantitative trait loci. To systematically identify biomarker signatures that mediate PD risk and pathogenesis, we analyzed comprehensive metabolome profiles from blood plasma in 149 PD patients and 150 controls. Multiple sphingolipids and fatty acid derivatives were perturbed in PD, and we identified both unique and shared features with the Alzheimer’s disease metabolome. A PD acylcarnitine signature was further replicated in metabolic data from human postmortem brain tissue, when comparing those with or without preclinical Lewy body pathology. Integrated analysis of complementary proteomic profiles from the same autopsy cohort revealed dysregulation of mitochondrial processes dependent on acylcarnitines, including fatty acid beta-oxidation, the tricarboxylic acid cycle, and oxidative phosphorylation. Our results reveal a causal chain linking genetic variation to altered gene/protein expression, lipid dysmetabolism, and the manifestation of PD.


  • Clinical Bioinformatician Body of Knowledge—Clinical Laboratory Regulation and Data Security Core

    by Ryan J. Schmidt, Larissa V. Furtado, Amber M. Fussell, Danielle Jordan, Matthew Lebo, Aijazuddin Syed, Robyn L. Temple-Smolkin, Eric Venner, Elizabeth Worthey, Alexis B. Carter


  • Open Access

    Celeste : A cloud-based genomics infrastructure with variant-calling pipeline suited for population-scale sequencing projects

    by Noora Siddiqui, Breanna Lee, Victoria Yi, Jesse Farek, Ziad Khan, Sara E Kalla, Qiaoyan Wang, Kimberly Walker, James Meldrim, Christopher Kachulis, et al.

    Background: The All of Us Research Program ( All of Us ) is one of the world’s largest sequencing efforts that will generate genetic data for over one million individuals from diverse backgrounds. This historic megaproject will create novel research platforms that integrate an unprecedented amount of genetic data with longitudinal health information. Here, we describe the design of Celeste , a resilient, open-source cloud architecture for implementing genomics workflows that has successfully analyzed petabytes of participant genomic information for All of Us – thereby enabling other large-scale sequencing efforts with a comprehensive set of tools to power analysis. The Celeste infrastructure is tremendously scalable and has routinely processed fluctuating workloads of up to 9,000 whole-genome sequencing (WGS) samples for All of Us , monthly. It also lends itself to multiple projects. Serverless technology and container orchestration form the basis of Celeste ’s system for managing this volume of data. Results: In 12 months of production (within a single Amazon Web Services (AWS) Region), around 200 million serverless functions and over 20 million messages coordinated the analysis of 1.8 million bioinformatics, quality control, and clinical reporting jobs. Adapting WGS analysis to clinical projects requires adaptation of variant-calling methods to enrich the reliable detection of variants with known clinical importance. Thus, we also share the process by which we tuned the variant-calling pipeline in use by the multiple genome centers supporting All of Us to maximize precision and accuracy for low fraction variant calls with clinical significance. Conclusions: When combined with hardware-accelerated implementations for genomic analysis, Celeste had far-reaching, positive implications for turn-around time, dynamic scalability, security, and storage of analysis for one hundred-thousand whole-genome samples and counting. Other groups may align their sequencing workflows to this harmonized pipeline standard, included within the Celeste framework, to meet clinical requisites for population-scale sequencing efforts. Celeste is available as an Amazon Web Services (AWS) deployment in GitHub, and includes command-line parameters and software containers.

  • Open Access

    Author Correction: The frequency of pathogenic variation in the All of Us cohort reveals ancestry-driven disparities

    by Eric Venner, Karynne Patterson, Divya Kalra, Marsha M. Wheeler, Yi-Ju Chen, Sara E. Kalla, Bo Yuan, Jason H. Karnes, Kimberly Walker, Joshua D. Smith, et al.

  • Open Access

    Defining and Reducing Variant Classification Disparities

    by Moez Dawood, Shawn Fayer, Sriram Pendyala, Mason Post, Divya Kalra, Karynne Patterson, Eric Venner, Lara A. Muffley, Douglas M. Fowler, Alan F. Rubin, et al.

    Background: Multiplexed Assays of Variant Effects (MAVEs) can test all possible single variants in a gene of interest. The resulting saturation-style data may help resolve variant classification disparities between populations, especially for variants of uncertain significance (VUS). Methods: We analyzed clinical significance classifications in 213,663 individuals of European-like genetic ancestry versus 206,975 individuals of non-European-like genetic ancestry from All of Us and the Genome Aggregation Database. Then, we incorporated clinically calibrated MAVE data into the Clinical Genome Resource’s Variant Curation Expert Panel rules to automate VUS reclassification for BRCA1, TP53, and PTEN . Results: Using two orthogonal statistical approaches, we show a higher prevalence ( p ≤5.95e-06) of VUS in individuals of non-European-like genetic ancestry across all medical specialties assessed in all three databases. Further, in the non-European-like genetic ancestry group, higher rates of Benign or Likely Benign and variants with no clinical designation ( p ≤2.5e-05) were found across many medical specialties, whereas Pathogenic or Likely Pathogenic assignments were higher in individuals of European-like genetic ancestry ( p ≤2.5e-05). Using MAVE data, we reclassified VUS in individuals of non-European-like genetic ancestry at a significantly higher rate in comparison to reclassified VUS from European-like genetic ancestry ( p =9.1e-03) effectively compensating for the VUS disparity. Further, essential code analysis showed equitable impact of MAVE evidence codes but inequitable impact of allele frequency ( p =7.47e-06) and computational predictor ( p =6.92e-05) evidence codes for individuals of non-European-like genetic ancestry. Conclusions: Generation of saturation-style MAVE data should be a priority to reduce VUS disparities and produce equitable training data for future computational predictors.